Clinical Trials | December 17, 2024
Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Akums Drugs will undertake this development and commercialization in India
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Subscribe To Our Newsletter & Stay Updated
